A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
- Status
- COMPLETED
- Phase
- PHASE3
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Status
- TERMINATED
- Phase
- PHASE3
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
- Status
- TERMINATED
- Phase
- PHASE2
Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
- Status
- TERMINATED
- Phase
- PHASE2